Evidence map›Paper›PMID 25264786›Full record

ArticlePloS one2014

Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.

Kun Hyoe Rhoo, Megan Granger, Joynita Sur, Changyong Feng, Harris A Gelbard, Stephen Dewhurst, Oksana Polesskaya

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kun Hyoe RhooDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Megan GrangerDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Joynita SurDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Changyong FengDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, United States of America.
Harris A GelbardDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America; Center for Neural Development and Disease, and Departments of Pediatrics and Neurology, University of Rochester Medical Center, Rochester, New York, United States of America.
Stephen DewhurstDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Oksana PolesskayaDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
University of Rochester Medical Center · US

Funding

Targeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4M
NIMH NIH HHS P01 MH064570NIMH NIH HHS P01 MH64570
6 · The paper itself

Abstract

Brain metastasis of breast cancer is an important clinical problem, with few therapeutic options and a poor prognosis. Recent data have implicated mixed lineage kinase 3 (MLK3) in controlling the in vitro migratory capacity of breast cancer cells, as well as the metastasis of MDA-MB-231 breast cancer cells from the mammary fat pad to distant lymph nodes in a mouse xenograft model. We therefore set out to test whether MLK3 plays a role in brain metastasis of breast cancer cells. To address this question, we used a novel, brain penetrant, MLK3 inhibitor, URMC099. URMC099 efficiently inhibited the migration of breast cancer cells in an in vitro cell monolayer wounding assay, and an in vitro transwell migration assay, but had no effect on in vitro cell growth. We also tested the effect of URMC099 on tumor formation in a mouse xenograft model of breast cancer brain metastasis. This analysis showed that URMC099 had no effect on the either the frequency or size of breast cancer brain metastases. We conclude that pharmacologic inhibition of MLK3 by URMC099 can reduce the in vitro migratory capacity of breast cancer cells, but that it has no effect on either the frequency or size of breast cancer brain metastases, in a mouse xenograft model.

Indexed as

AnimalsBrain NeoplasmsBreast NeoplasmsCell Line, TumorCell MovementDisease Models, AnimalFemaleMAP Kinase Kinase KinasesMiceMice, NudeMitogen-Activated Protein Kinase Kinase Kinase 11Neoplasm TransplantationProtein Kinase InhibitorsPyridinesPyrrolesTransplantation, HeterologousMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11Protein Kinase InhibitorsPyridinesPyrrolesURMC-099

Identifiers

PMID25264786
PMCPMC4180451
OpenAlexW2007664557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.